Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.580 +0.120 (+8.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Expert Ratings for Pliant Therapeutics
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
 
Via Benzinga
Recap: Pliant Therapeutics Q1 Earnings
 
Via Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
What 12 Analyst Ratings Have To Say About Pliant Therapeutics
 
Via Benzinga
Pliant Therapeutics Shares Fall After Long-Term Data Of Bexotegrast In Lung Fibrosis Study
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Expert Ratings for Pliant Therapeutics
 
Via Benzinga
The Latest Analyst Ratings for Pliant Therapeutics
 
Via Benzinga
9 Analysts Have This to Say About Pliant Therapeutics
 
Via Benzinga
First Republic Bank, Top Financial And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Nasdaq falling around 17 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results
U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up... 
Via Benzinga
Why First Republic Bank Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket
Gainers Hongli Group Inc. (NASDAQ: HLP) gained 317.8% to $17.55 in pre-market trading. Hongli Group recently announced pricing of $8.25 million initial public offering of 2,062,500 ordinary shares at a... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
 
Via Benzinga
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy for 100% Returns
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
 
Via Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
Phase 1 clinical study initiation expected in the second quarter of 2023 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Pliant Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.